Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px
Document › Details

Crescendo Biologics Ltd.. (4/27/23). "Press Release: Crescendo Biologics Appoints Angus Hone as Chief Financial Officer". Cambridge.

Organisations Organisation Crescendo Biologics Ltd.
  Organisation 2 Instinctif Partners Life Sciences
  Group Instinctif Partners (Group)
Products Product CB307 (Crescendo Biologics)
  Product 2 Humabody® VH platform
Persons Person Booth, Michael (Mike) (Bit Bio 202308 SVP External Affairs before Crescendo Biologics + Incyte + Algeta + Trout Group)
  Person 2 Harold, Theodora (Crescendo Biologics 201905– CEO before CFO before PsiOxus + Mission Tx + OrthoMimectics + Cytomax)
     


Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces the appointment of Angus Hone as Chief Financial Officer. Angus is an experienced corporate finance executive who has spent over 20 years in CFO and other leadership positions within and advising dynamic life sciences and technology companies as well as other IP-intensive start-up and scale-up businesses in the UK. Angus will replace Dr Michael Booth, who is leaving Crescendo to pursue an alternative opportunity in the global biopharma sector.

“We are delighted to welcome Angus to the Crescendo team. This is a very exciting time for Crescendo Biologics and especially for CB307, our lead clinical development programme, and I am thrilled that Angus will be able to provide a seamless leadership transition with his wealth of operational experience,” commented Theodora Harold, CEO at Crescendo Biologics. “Meanwhile, we are extremely grateful to Mike for all his contributions to Crescendo and wish him every success in the future.”

CB307 is Crescendo’s most advanced in-house development programme which is now entering the cohort expansion part of the ongoing first in human Phase 1a/1b clinical trial (NCT04839991). CB307 is a first-in-class, half-life extended, CD137 x PSMA bispecific, designed to deliver a safer and more durable T cell response to cancer. CB307 was developed by Crescendo using its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody® VH).


-Ends-


For more information, please contact:

Crescendo Biologics
Theodora Harold, CEO
Angus Hone, CFO
+ 44 (0)1223 497140
investors@crescendobiologics.com
media@crescendobiologics.com

Instinctif Partners
Melanie Toyne-Sewell
Adam Loudon
+ 44 (0)20 7457 2020
crescendo@instinctif.com


About Crescendo Biologics

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo’s T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody.

The Company’s ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications.

Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital.

For more information, please visit www.crescendobiologics.com and follow @HUMABODY.

   
Record changed: 2024-01-20

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Crescendo Biologics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px




» top